다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Coeptis Therapeutics Holdings Inc (COEP)
Coeptis Therapeutics Holdings Inc (COEP) 뉴스

COEP

Coeptis Therapeutics (COEP)

Coeptis Therapeutics Holdings Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:COEP

일자	시간	출처	헤드라인	심볼	기업
2025/01/01	04:20	AllPennyStocks.com	Trading Halt Occurred During This Micro Cap's EOY Surge	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/12/27	22:15	PR Newswire (US)	Coeptis Therapeutics Announces Reverse Stock Split	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/12/26	22:15	PR Newswire (US)	Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/12/12	22:00	PR Newswire (US)	Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/12/03	22:15	PR Newswire (US)	Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/11/07	22:07	PR Newswire (US)	Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/10/24	21:07	PR Newswire (US)	Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/10/15	21:07	PR Newswire (US)	Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/09/19	20:07	PR Newswire (US)	Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/09/05	21:07	PR Newswire (US)	Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/08/17	05:02	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/08/17	05:01	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/08/15	06:26	Edgar (US Regulatory)	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/08/15	06:25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/08/01	06:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/06/20	21:47	PR Newswire (US)	Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/05/30	21:47	PR Newswire (US)	Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/05/08	21:47	PR Newswire (US)	Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/05/02	21:47	PR Newswire (US)	Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/04/02	21:47	PR Newswire (US)	Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/02/26	23:00	PR Newswire (US)	Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/02/07	21:30	PR Newswire (US)	Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2024/01/04	21:30	PR Newswire (US)	Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2023/10/31	22:01	PR Newswire (US)	Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2023/10/24	21:30	PR Newswire (US)	Coeptis Therapeutics Announces $2 Million Private Placement	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2023/10/11	20:30	PR Newswire (US)	Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2023/10/09	22:15	PR Newswire (US)	Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2023/10/04	20:30	PR Newswire (US)	Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2023/09/27	20:30	PR Newswire (US)	Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc
2023/09/14	20:30	PR Newswire (US)	Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection	NASDAQ:COEP	Coeptis Therapeutics Holdings Inc

검색 관련기사 보기:NASDAQ:COEP

Invesco QQQ Trust Series 1

US Dollar vs Euro

American Express

US Dollar vs Sterling

Verizon Communications

Health Care Select Sector

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관